Safety Tolerability and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis

  • STATUS
    Recruiting
  • End date
    Aug 25, 2023
  • participants needed
    400
  • sponsor
    Gilead Sciences
Updated on 8 September 2021
Investigator
Gilead Study Team
Primary Contact
Cambridge University Hospitals NHS Foundation Trust (6.1 mi away) Contact
+231 other location
platelet count
fibrosis
cilofexor

Summary

The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).

Details
Condition Primary Sclerosing Cholangitis
Treatment Placebo, Cilofexor
Clinical Study IdentifierNCT03890120
SponsorGilead Sciences
Last Modified on8 September 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note